Anzurstobart (CC-95251; BMS-986351) is a fully human monoclonal antibody targeting SIRP?? with high affinity. This antibody effectively inhibits the interaction between CD47 and SIRP??, a critical pathway that tumors exploit to evade immune destruction. By blocking this interaction, Anzurstobart enhances the phagocytic activity of macrophages, particularly in co-culture models of diffuse large B-cell lymphoma (DLBCL) when used in conjunction with Rituximab. This antibody is primarily researched for its therapeutic potential in both solid tumors and hematological malignancies, offering significant insights into immune checkpoint blockade strategies.
Anzurstobart (CC-95251; BMS-986351) is a fully human monoclonal antibody targeting SIRP?? with high affinity. This antibody effectively inhibits the interaction between CD47 and SIRP??, a critical pathway that tumors exploit to evade immune destruction. By blocking this interaction, Anzurstobart enhances the phagocytic activity of macrophages, particularly in co-culture models of diffuse large B-cell lymphoma (DLBCL) when used in conjunction with Rituximab. This antibody is primarily researched for its therapeutic potential in both solid tumors and hematological malignancies, offering significant insights into immune checkpoint blockade strategies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
